New evidence shows that extended estrogen suppression treatment using an aromatase inhibitors for hormone receptor-positive postmenopausal breast cancer is safe; it does not increase the risk of coronary artery calcification, a sign of active coronary atherosclerosis, as some prior studies had indicated.